KVD824
KVD824-201
Phase 2 small_molecule terminated
Quick answer
KVD824 for Angioedema, Hereditary, Types I and II is a Phase 2 program (small_molecule) at KalVista Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- KalVista Pharmaceuticals
- Indication
- Angioedema, Hereditary, Types I and II
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated